Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Odyssey Therapeutics
Biotech
Odyssey saga continues with $213M series D
The haul will finance clinical proof-of-concept studies across several of Odyssey's internally developed programs as well as support preclinical work.
Darren Incorvaia
Sep 10, 2025 8:00am
Odyssey abandons IPO plans as 'not in best interests of company'
Jun 10, 2025 7:25am
Odyssey, Sionna join band of biotechs braving the IPO waters
Jan 21, 2025 5:27am
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
Odyssey raises epic $101M to push programs off to clinical sea
Dec 5, 2023 11:01am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
